Regenerative cell therapy for rare heart disease enters PhII trials
Longeveron has completed enrolment for its Phase IIb clinical trial (ELPIS II) evaluating cellular therapy laromestrocel as a potential adjunct treatment for Hypoplastic Left Heart Syndrome (HLHS). Laromestrocel is a scalable, allogeneic cellular therapy being evaluated in multiple indications. Top-line trial results are anticipated in… Read More